Jeff Conn

The BRET Office of Career Development’s 2026 annual career symposium brought together Vanderbilt alums and other professionals to showcase the diverse career paths available to biomedical trainees once they graduate. Through panel discussions, networking opportunities, and personal career stories, trainees gained valuable insights into careers spanning medical communications, medical affairs, industry, consulting, and beyond. Read More

Ashley Brady, PhD’03, assistant dean of biomedical career engagement and strategic partnerships in the BRET Office of Career Development ASPIRE Program and associate professor of medical education and administration, sat down with us to discuss her experience studying basic science at Vanderbilt and how it played a role in her career. Read More

Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming cutting-edge research into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read More

Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming Vanderbilt researchers’ work into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read More

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read More

Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s  Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work… Read More

Vanderbilt University has honored 35 retiring faculty members for their years of service by bestowing upon them the title of emerita or emeritus faculty. They were recognized during Vanderbilt’s Commencement ceremony on May 13. A faculty member who has served the university with distinction over a period of years and… Read More

A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read More

Vanderbilt University has signed an exclusive, worldwide license and a research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.   The licensed program centers around the M4 muscarinic receptor positive allosteric modulator—including… Read More

THE IDEA   Jeffrey Conn (John Russell/Vanderbilt University) James Maksymetz A new study led by Jeff Conn, Lee E. Limbird Chair in Pharmacology, James Maksymetz, a former graduate student in the Conn laboratory, and other collaborators at the Warren Center for… Read More